The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis by unknown
1 3
Hum Genet (2017) 136:129–148
DOI 10.1007/s00439-016-1753-8
REVIEW
The molecular pathogenesis of schwannomatosis, a paradigm 
for the co‑involvement of multiple tumour suppressor genes 
in tumorigenesis
Hildegard Kehrer‑Sawatzki1  · Said Farschtschi2 · Victor‑Felix Mautner2 · 
David N. Cooper3 
Received: 11 October 2016 / Accepted: 27 November 2016 / Published online: 5 December 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
harbouring not only SMARCB1 and LZTR1 but also NF2. 
Thus, schwannomatosis is paradigmatic for a tumour pre-
disposition syndrome caused by the concomitant muta-
tional inactivation of two or more tumour suppressor genes. 
This review provides an overview of current models of 
tumorigenesis and mutational patterns underlying schwan-
nomatosis that will ultimately help to explain the complex 
clinical presentation of this rare disease.
Introduction
Schwannomatosis (MIM #162091) is a rare disorder with 
an estimated incidence of 1/40,000–1/70,000 (Koontz et al. 
2013) that is characterized by the occurrence of multiple 
schwannomas and, much less commonly, meningiomas. 
In patients with schwannomatosis, schwannomas com-
monly affect the spine (74%) and peripheral nerves (89%), 
whereas cranial nerve schwannomas (mostly trigeminal) 
are uncommon (8%) (Merker et al. 2012). In one-third of 
patients with schwannomatosis, the tumours are anatomi-
cally limited to a single limb or several contiguous seg-
ments of the spine or one half of the body (MacCollin 
et al. 1996; Merker et al. 2015). The most common symp-
tom reported by schwannomatosis patients is chronic pain 
which may be either local or diffuse (MacCollin et al. 
2005; Merker et al. 2015).
Considerable overlap has been noted between schwan-
nomatosis and NF2 (MIM #101000) in terms of the occur-
rence of the associated types of tumour, but both diseases 
are regarded as separate clinical entities (MacCollin et al. 
1996, 2003; Evans et al. 1997; reviewed by Blakeley and 
Plotkin 2016). Despite this clinical overlap, there are sev-
eral important differences between schwannomatosis and 
NF2 in relation to the frequency of specific tumour types 
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and the occurrence of certain clinical symptoms (see Table 1 
and references therein). Intradermal schwannomas, epend-
ymomas, cataract, and retinal abnormalities are all observed 
in patients with NF2 but are not associated with schwanno-
matosis. Furthermore, bilateral vestibular schwannomas, the 
hallmark feature of NF2, have not been reported in patients 
with schwannomatosis. However, unilateral vestibular 
schwannomas may occur in association with schwannoma-
tosis and hence cannot be used as an exclusion criterion to 
distinguish between schwannomatosis and NF2 (Smith et al. 
2012a, 2015, 2016; Wu et al. 2015; Mehta et al. 2016).
The majority of patients with schwannomatosis are spo-
radic, whereas 13–25% are familial cases (Evans et al. 1997; 
Antinheimo et al. 2000; MacCollin et al. 2005; Merker et al. 
2012). A combination of linkage analysis in affected fami-
lies and mutation screening of the NF2 gene in schwanno-
mas indicated that schwannomatosis is not due to germline 
mutations in the NF2 gene (Jacoby et al. 1997; Kaufman 
et al. 2003; MacCollin et al. 2003). However, instead of con-
stitutional (germline) NF2 mutations, independent somatic 
mutations affecting both NF2 alleles are frequently found 
in schwannomas of patients with schwannomatosis (Jacoby 
et al. 1997; Kaufman et al. 2003; Boyd et al. 2008; Hadfield 
et al. 2008; Sestini et al. 2008; Hutter et al. 2014; Paganini 
et al. 2015a; Piotrowski et al. 2014; Smith et al. 2015, 2016).
So far, two schwannomatosis predisposition genes have 
been identified, SMARCB1 and LZTR1 (Hulsebos et al. 
2007; Sestini et al. 2008; Hadfield et al. 2008; Smith et al. 
Table 1  Clinical overlap and differences between NF2 and schwannomatosis
a Patients with unilateral vestibular schwannoma and other NF2-related tumours who fulfil the Manchester criteria (Evans et al. 2005) have a 
high risk of developing a contralateral tumour, especially if the patients are younger than 18 years of age at the time of diagnosis (Evans et al. 
2008). Furthermore, 60% of patients with unilateral vestibular schwannomas exhibit somatic mosaicism for an NF2 mutation (Evans et al. 2007)
b To date, germline LZTR1 mutations have been identified in five patients with unilateral vestibular schwannoma and at least two nonvestibular, 
nonintradermal schwannomas (Smith et al. 2012a, 2015, 2016). A germline SMARCB1 mutation has been identified in a single family with uni-
lateral vestibular schwannoma (Wu et al. 2015). Mehta et al. (2016) have also reported a schwannomatosis patient exhibiting a unilateral vestibu-
lar schwannoma but without germline SMARCB1 or LZTR1 mutations
c Subcutaneous tumours are histologically schwannomas of peripheral nerves visible as nodular tumours
d Skin plaques are discrete, well-circumscribed, and slightly raised cutaneous lesions usually less than 2 cm in diameter. They are regarded as 
schwannomas and exhibit a rough surface often with hyperpigmentation and excessive hair
Clinical features Frequency of clinical feature
NF2 (references) Schwannomatosis (references)
Bilateral vestibular schwannoma 90–95% Evans et al. (1992), Parry et al. (1994), 
Mautner et al. (1996)
Absent MacCollin et al. (1996), Merker et al. 
(2012)
Unilateral vestibular schwannoma 18%a Evans et al. (1999) Rareb
Intracranial nonvestibular schwannoma 24–51% Parry et al. (1994), Mautner et al. (1996), 
Fisher et al. (2007)
9–10% Merker et al. (2012), Li et al. (2016)
Intracranial meningioma 45–58% Evans et al. (1992), Parry et al. (1994), 
Mautner et al. (1996), Patronas et al. 
(2001)
5% Merker et al. (2012)
Spinal tumour 63–90% Parry et al. (1994), Mautner et al. (1996), 
Patronas et al. (2001), Dow et al. 
(2005), Mautner et al. (1995), Rennie 
et al. (2008)
74% Merker et al. (2012)
Ependymoma 18–58% Dow et al. (2005), Mautner et al. (1995), 
Rennie et al. (2008), Plotkin et al. 
(2011)
Absent Gonzalvo et al. (2011), Merker et al. 
(2012)
Peripheral nerve schwannoma 68% Evans et al. (1992) 89% Merker et al. (2012)
Subcutaneous tumourc 43–48% Evans et al. (1992), Mautner et al. 
(1997)
23% Merker et al. (2012)
Skin plaquesd 41–48% Evans et al. (1992), Mautner et al. 
(1997)
Absent Merker et al. (2012)
Intradermal tumour 27% Evans et al. (1992) Absent MacCollin et al. (1996)
Retinal hamartoma 6–22% Parry et al. (1994), Mautner et al. (1996), 
Ragge et al. (1997)
Absent MacCollin et al. (1996)
Epiretinal membrane 12–40% Bosch et al. (2006), Ragge et al. (1995) Absent MacCollin et al. (1996)
Subcapsular cataract 60–81% Evans et al. (1992), Parry et al. (1994), 
Bosch et al. (2006)
Absent MacCollin et al. (1996)
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2012b; Hutter et al. 2014; Piotrowski et al. 2014; Smith 
et al. 2015). Further schwannomatosis predisposition genes 
may well exist, but they still remain to be discovered. The 
clinical overlap between schwannomatosis and NF2 ren-
ders differential diagnosis somewhat difficult, particularly 
in sporadic and mosaic cases with multiple schwannomas 
but without bilateral vestibular schwannomas and detect-
able germline NF2 gene mutations. However, compre-
hensive mutation testing of LZTR1, SMARCB1, and NF2 
using DNA derived from blood and different tumour sam-
ples of the patient is the method of choice to distinguish 
between the two conditions (Castellanos et al. 2015; Smith 
et al. 2016). The diagnosis of schwannomatosis is predi-
cated upon the molecular and/or clinical diagnostic criteria 
according to Plotkin et al. (2013) and Ostrow et al. (2016) 
(Fig. 1). In what follows, we review current knowledge of 
the mutational patterns of the known schwannomatosis pre-
disposing genes, models of tumorigenesis, and the geno-
type/phenotype relationship.
SMARCB1 germline mutations in patients 
with schwannomatosis
Linkage analysis with microsatellite markers performed in 
families affected with schwannomatosis served to exclude 
the NF2 gene as a germline-transmissible schwannomato-
sis predisposition gene but nevertheless suggested that such 
a gene could be located within an 8.48-Mb region centro-
meric to NF2, between markers D22S420 and D22S1148 
in the vicinity of D22S1174 on chromosome 22 (MacCol-
lin et al. 2003) (Fig. 2). This region includes SMARCB1 
(also termed hSNF5 or INI1) which encompasses nine 
exons encoding a subunit of the human SWI/SNF chro-
matin-remodeling complex (reviewed by Kalimuthu and 
Chetty 2016). SMARCB1 appears not to be essential for 
the assembly of the remodeling complex (Doan et al. 2004) 
but is involved in targeting the SWI/SNF complex to gene 
promoters (Kuwahara et al. 2013). SMARCB1 also partici-
pates in a number of protein–protein interactions involv-
ing transcription factors, such as c-MYC and GLI1 (Cheng 
et al. 1999; Jagani et al. 2010; Stojanova et al. 2016). 
Biallelic SMARCB1 inactivation has been detected in a 
multitude of different tumour types and at high frequency 
in rhabdoid tumours (reviewed by Roberts and Biegel, 
2009; Hollmann and Hornick 2011; Masliah-Planchon 
et al. 2015). Using a candidate gene approach, Hulsebos 
et al. (2007) investigated whether SMARCB1 might be the 
anticipated schwannomatosis predisposition gene. They 
subsequently found a germline mutation of SMARCB1 in 
exon 1 (c.34C > T) that was predicted to result in prema-
ture translational termination at protein position p.Gln12* 
in a 22-year-old female patient and her affected father. In 
one schwannoma from the father, Hulsebos et al. (2007) 
detected an additional somatic truncating SMARCB1 muta-
tion (c.544C > T; p.Gln182*). In a second schwannoma 
from the same individual, the partial loss of the SMARCB1 
wild-type allele was observed. These findings constituted 
good prima facie evidence that SMARCB1 functions as a 
tumour suppressor gene and that mutations in this gene pre-
dispose to schwannomatosis. Since this initial report, fur-
ther studies have confirmed this conclusion, since germline 
SMARCB1 mutations have been identified in schwanno-
matosis patients from different cohorts (Supp. Table S1) 
(Boyd et al. 2008; Hadfield et al. 2008; Sestini et al. 2008; 
Rousseau et al. 2011; Smith et al. 2012b, 2014; Asai et al. 
2015). These studies imply that germline SMARCB1 muta-
tions are present in at least 48% of familial and 9.8% of 
sporadic schwannomatosis cases (Supp. Table S2).
Fig. 1  Diagnostic criteria for schwannomatosis according to Ostrow 
et al. (2016) and Plotkin et al. (2013) based upon the criteria formu-
lated by MacCollin et al. (2005) which predated our ability to per-
form molecular testing for schwannomatosis and did not consider the 
possibility of multiple meningiomas. a According to the findings of 
Castellanos et al. (2015), the deletions of 22q causing the LOH in ≥ 
2 tumours should have different breakpoints for these deletions to 
be considered as independent events. The analysis of the extent of 
the LOH is necessary to exclude a large 22q deletion as the first-hit 
mutation (that would be identical in different tumours) which would 
be indicative of mosaic NF2. If an identical SMARCB1 mutation is 
detected in different tumours of a patient, SMARCB1-associated 
schwannomatosis may be diagnosed. LZTR1-associated schwanno-
matosis may be present, if an identical LZTR1 mutation is detected 
in different tumours of a patient. b High-quality MRI should include 
a detailed study of the internal auditory canal with slices no more 
than 3 mm thick. c Schwannomatosis should be considered as a pos-
sible diagnosis if two or more nonintradermal tumours are present, 
even if none has been pathologically confirmed to be a schwannoma; 
the occurrence of chronic pain in association with the tumour(s) 
increases the likelihood of schwannomatosis (Plotkin et al. 2013). d 
Smith et al. (2016) identified five patients, with unilateral vestibular 
schwannomas and at least two nonvestibular, nonintradermal schwan-
nomas, who met the diagnostic criteria for NF2 but had germline 
LZTR1 mutations instead of germline NF2 mutations. 22q LOH: loss 
of heterozygosity on the long arm of chromosome 22
132 Hum Genet (2017) 136:129–148
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Meningiomas in patients with schwannomatosis 
and germline SMARCB1 mutations
Biallelic inactivation of SMARCB1 has been observed 
in both schwannomas and meningiomas of patients with 
schwannomatosis (Boyd et al. 2008; Sestini et al. 2008; Had-
field et al. 2008, 2010a; Smith et al. 2012b). Meningiomas 
occur in 5% of schwannomatosis patients (Merker et al. 
2012) and appear to be located predominantly in the cerebral 
falx (van den Munckhof et al. 2012). Three different families 
have been identified in which some members harboured ger-
mline SMARCB1 mutations and exhibited multiple schwan-
nomas and meningiomas (Bacci et al. 2010; Christiaans et al. 
2011; van den Munckhof et al. 2012; Melean et al. 2012) 
(Supp. Table S3). However, not all mutation carriers in these 
families had meningiomas, indicative of the variable expres-
sion of meningiomas in patients with germline SMARCB1 
mutations. Furthermore, SMARCB1 germline mutations 
have not been found in patients with multiple meningiomas 
in the absence of schwannomatosis (Hadfield et al. 2010b). 
Multiple meningiomas are very rare and usually occur in 
the context of NF2 (reviewed by Smith 2015). Remarkably, 
germline mutations in SMARCE1, another component of the 
SWI/SNF chromatin-remodeling complex, have been iden-
tified in patients with familial multiple spinal meningiomas 
without NF2 (Smith et al. 2013).
Coffin–Siris syndrome, schwannomatosis, and SMARCB1 
germline mutation
Recently, a patient with Coffin–Siris syndrome (MIM# 
135900) and schwannomatosis has been reported to carry 
a germline missense mutation in exon 9 of SMARCB1 
(c.1121G > A; p.Arg374Gln) (Gossai et al. 2015). The 
patient exhibited intellectual disability, hypotonia, micro-
cephaly, coarse face, hypoplasia of the digits, general 
hirsutism, multiple schwannomas, as well as bilateral cat-
aracts and bilateral cranial nerve schwannomas which are 
most unusual in the context of schwannomatosis. Patients 
with Coffin–Siris syndrome and germline SMARCB1 muta-
tions have been previously reported, but none have exhib-
ited schwannomas (Tsurusaki et al. 2012).
Mutational pattern in SMARCB1‑positive 
schwannomas as compared with rhabdoid tumours
The recognition that mutations in the SMARCB1 gene pre-
dispose to benign schwannoma, which usually become 
symptomatic during adulthood, came as something of a 
surprise, since this gene was originally discovered in the 
context of its involvement in the development of atypi-
cal teratoid/rhabdoid tumours (Versteege et al. 1998; 
Sévenet et al. 1999a). These highly malignant tumours 
develop most commonly in the central nervous system in 
very young children who frequently die as a consequence 
of the malignancy before the age of 3 (Hilden et al. 2004; 
Lau et al. 2015). A few patients have been reported to have 
survived the initial tumour for up to 26 years, albeit with 
multiple recurrences (reviewed by Takahashi-Fujigasaki 
et al. 2012). Rhabdoid tumours may also develop in the 
kidney and less frequently, in extrarenal tissues (reviewed 
by Oda and Tsuneyoshi 2006), and SMARCB1 mutations 
have been identified in both renal and extrarenal rhabdoid 
tumours (Biegel et al. 2002; Savla et al. 2000; Kordes 
et al. 2010). Germline mutations of SMARCB1 occur in 
approximately one-third of patients with rhabdoid tumours 
(Biegel et al. 1999; Sévenet et al. 1999b; Bourdeaut et al. 
2011; Eaton et al. 2011). Although most of the germline 
SMARCB1 mutations causing rhabdoid tumours occur de 
novo, familial cases have also been reported, with several 
affected members harbouring constitutional SMARCB1 
mutations and malignant rhabdoid tumours but never 
Fig. 2  Partial ideogram of chromosome 22 indicating the location of 
the LZTR1, SMARCB1, and NF2 genes and the microsatellite mark-
ers D22S420 (GenBank accession number Z23643.1), D22S1174 
(GenBank acc. No. Z51327.1), and D22S1148 (GenBank acc. No. 
Z52647.1). The nucleotide numbering is given according to hg19. 
Linkage analysis provided the original evidence that the schwanno-
matosis predisposition genes are located within the ~8.5-Mb region 
between markers D22S420 and D22S1148 (MacCollin et al. 2003). 
The centromeric direction is on the left side, the telomeric direction is 
on the right side of the schema
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developing schwannomas (Sévenet et al. 1999b; Tay-
lor et al. 2000; Ammerlaan et al. 2008). This condition is 
known as rhabdoid tumour predisposition syndrome 1 
(RTPS1: MIM#609322). In some cases, RTPS1 is caused 
by gonadal mosaicism for an SMARCB1 mutation (Sévenet 
et al. 1999b; Bruggers et al. 2011; Lee et al. 2002; Janson 
et al. 2006; Eaton et al. 2011; Gigante et al. 2016). Tumo-
rigenesis in RTPS1 is driven by somatically acquired sec-
ond-hit mutations in the wild-type SMARCB1 allele. Bial-
lelic inactivation of SMARCB1 through the acquisition of 
two somatic mutations has been observed in the rhabdoid 
tumours of patients without germline mutations. Hence, 
SMARCB1 plays the role of a classic tumour suppressor 
gene in rhabdoid tumours according to the Knudson two-
hit model (Versteege et al. 1998; Biegel et al. 1999; Uno 
et al. 2002; Jackson et al. 2009; Kordes et al. 2010; Bour-
deaut et al. 2011).
In contrast to the highly malignant rhabdoid tumours, 
schwannomas are generally benign and very rarely trans-
form to malignant tumours (reviewed by Carter et al. 2012). 
Differences in the position and type of germline SMARCB1 
mutations have been observed in patients with schwanno-
matosis compared to those with rhabdoid tumours. Schwan-
nomatosis-associated SMARCB1 mutations are preferen-
tially located either at the 5′or 3′ end of the gene (Hulsebos 
et al. 2007; Hadfield et al. 2008; Rousseau et al. 2011; Smith 
et al. 2012b, 2014). Several recurrent SMARCB1 mutations 
have been identified in patients with schwannomatosis; the 
most common of these is the c.*82C > T mutation located 
in the 3′UTR (Supp. Table S4). By contrast, intragenic ger-
mline SMARCB1 mutations observed in patients with rhab-
doid tumour tend to be located in the central part of the 
gene (Smith et al. 2014). In addition to this position effect, 
the mutational spectra differ, with SMARCB1 mutations in 
schwannomatosis patients being predominantly nontruncat-
ing, including missense and splice-site mutations as well as 
in-frame deletions, that lead to the production of stable tran-
scripts (Smith et al. 2012c). By contrast, almost all germline 
mutations of SMARCB1 in patients with rhabdoid tumour 
are either protein-truncating or alternatively whole-gene or 
multi-exon deletions (Bourdeaut et al. 2011; Eaton et al. 
2011; Smith et al. 2014; reviewed by Biegel et al. 2014). 
These findings are suggestive of a genotype/phenotype cor-
relation: loss-of-function mutations occur in patients with 
rhabdoid tumours, whereas schwannomatosis-associated 
germline SMARCB1 mutations are predominantly hypomor-
phic (Smith et al. 2012c, 2014).
In accord with this postulate are the findings of Hulse-
bos et al. (2014a). These authors analysed four schwanno-
matosis-associated SMARCB1 mutations that were located 
in the 5′ region of the gene and were predicted to intro-
duce a premature translational termination codon (PTC). 
Two of them, c.30delC (p.Phe10Leufs*6) and c.38delA 
(p.Lys13Serfs*3), may be predicted to cause frameshifts 
generating a PTC starting at nucleotide 44. The other two 
SMARCB1 mutations, c.34C > T (p.Gln12*) and c.46A > T 
(p.Lys16*), directly generate PTCs at their respective posi-
tions. Although transcripts containing these PTCs may rea-
sonably be expected to be degraded by nonsense-mediated 
mRNA decay (NMD), stable transcripts were detected by 
Hulsebos et al. (2014a) in schwannoma tissue obtained 
from two patients harbouring either c.34C > T or c.30delC. 
Furthermore, Western blot analysis using frozen tumour tis-
sue from the individual with c.30delC indicated the occur-
rence of a shortened protein owing to downstream transla-
tional reinitiation. This finding was confirmed by transient 
overexpression of a c.34C > T-containing expression vector 
in a cell line without endogenous SMARCB1 protein and 
subsequent detection of the shortened SMARCB1 pro-
tein by Western blotting. Similar overexpression experi-
ments indicated that the mutations c.30delC, c.38delA, and 
c.46A > T also lead to truncated SMARCB1 proteins which 
may well be partially functional (Hulsebos et al. 2014a).
Many of the missense and splice-site mutations as well 
as in-frame deletions detected in schwannomatosis patients 
fail to alter SMARCB1 transcript stability, and hence, the 
mutant alleles are likely to encode at least partially func-
tional proteins, as has been concluded from cyclin D1 
repression assays (Smith et al. 2012c). Loss of SMARCB1 
in rhabdoid tumours leads to upregulation of cyclin D1 
and cell cycle progression. A cyclin D1 repression assay 
has shown that mutant SMARCB1 proteins, derived from 
expression plasmids harbouring the same missense and 
splice-site mutations noted in patients with schwanno-
matosis, were capable of suppressing cyclin D1 activity 
in a similar manner to the wild-type SMARCB1 protein 
(Smith et al. 2012c). Taken together, these observations 
suggest that in schwannomatosis, germline SMARCB1 
mutations encode proteins with some residual functional-
ity (Smith et al. 2012c; Hulsebos et al. 2014a). By contrast, 
SMARCB1 mutations in rhabdoid tumours and patients 
with RTPS1 are almost invariably either nonsense muta-
tions or frameshifts, even complete gene deletions, and 
hence are associated with a loss-of-function (Kordes et al. 
2010; Bourdeaut et al. 2011; reviewed by Biegel et al. 
2014). Consequently, SMARCB1 expression is completely 
absent in rhabdoid tumours (Hoot et al. 2004; Judkins et al. 
2004; Haberler et al. 2006; Sigauke et al. 2006; Kordes 
et al. 2010; reviewed by Margol and Judkins 2014).
Mosaic SMARCB1 expression 
in schwannomatosis‑associated schwannomas
Schwannomas in patients with germline SMARCB1 muta-
tions have been reported to exhibit a mosaic SMARCB1 
protein expression pattern by immunohistochemical 
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staining of tumour sections with the monoclonal BAF47 
antibody specific for the C-terminal part of SMARCB1 
raised against amino acids 257–359 (Hulsebos et al. 2007; 
Patil et al. 2008; Smith et al. 2012c). This mosaic pattern 
results from mixed immuno-positive and -negative nuclei, 
consistent with the expression of SMARCB1 in a sub-
set of tumour cells. Considerable inter- and intra-tumoral 
variability has been observed with regard to the number 
of nuclei that exhibit SMARCB1 expression (Patil et al. 
2008). The mosaic expression pattern may be explicable 
in terms of a subset of schwannoma cells retaining the 
wild-type SMARCB1 allele, thereby enabling the synthe-
sis of sufficient SMARCB1 protein to give rise to positive 
immunostaining of the respective nuclei. In other types 
of tumour cell, however, the loss of the SMARCB1 wild-
type allele leads to complete loss of protein expression. 
Although this scenario may account for some schwan-
nomas, it cannot explain the mosaic SMARCB1 immu-
nostaining observed in the majority of these tumours. This 
may be concluded from the observation that the loss of the 
wild-type SMARCB1 allele is readily detectable by loss of 
heterozygosity (LOH) analysis using polymorphic mark-
ers, suggesting that this loss affects a large proportion of 
tumour cells. Consequently, the mosaic SMARCB1 expres-
sion is most likely related to the hypomorphic nature of 
the mutations in schwannomatosis patients that encode 
stable mRNA transcripts giving rise to detectable amounts 
of SMARCB1 protein. Since, in schwannomas of patients 
with schwannomatosis, the wild-type SMARCB1 allele is 
often lost by deletion or monosomy 22, the SMARCB1 
protein detected in schwannoma cells must be encoded by 
the mutant allele. The inability to detect mutant proteins in 
all tumour cells by immunostaining is likely to be a con-
sequence of the instability of mutant SMARCB1 proteins 
(Hulsebos et al. 2014a). This instability results in immuno-
logically nonreactive SMARCB1 protein degradation prod-
ucts in a proportion of the schwannoma cells. Since this 
degradation is likely to be a random process, some cells 
may still express detectable amounts of SMARCB1 protein 
resulting in a mosaic expression pattern when analysing 
schwannoma tissue sections (Hulsebos et al. 2014a, 2016).
Recently, an N-terminal region of SMARCB1 has been 
identified that encodes a winged helix DNA-binding 
domain (Allen et al. 2015). This domain is deleted from the 
shortened SMARCB1 proteins encoded by the transcripts 
harbouring exon 1 truncating mutations investigated by 
Hulsebos et al. (2014a). Furthermore, N-terminally located 
SMARCB1 missense mutations are predicted to destabilize 
the encoded protein and interfere with DNA-binding (Allen 
et al. 2015). Despite the reduced stability and impaired 
DNA-binding capacity of proteins encoded by transcripts 
harbouring mutations located within the N-terminal half 
of SMARCB1, it would appear that these proteins retain 
sufficient residual function to prevent the occurrence of 
highly malignant rhabdoid tumours during the early child-
hood in patients with complete loss-of-function SMARCB1 
mutations.
Malignancy in patients with SMARCB1 germline 
mutations and schwannomatosis
Three families have been reported with germline 
SMARCB1 mutation carriers presenting either with 
rhabdoid tumours or schwannomatosis (Swensen et al. 
2009; Eaton et al. 2011; Sredni and Tomita 2015). The 
SMARCB1 mutations identified in these families were pre-
dicted to introduce premature termination codons leading 
to the production of unstable transcripts that would then 
undergo nonsense-mediated mRNA decay (Supp. Table 
S5). Somatic mosaicism for the SMARCB1 mutation in 
the family members affected only by schwannomas cannot 
explain the absence of rhabdoid tumours in these patients. 
The existence of adult mutation carriers in these families 
without rhabdoid tumours is intriguing and suggests that 
the risk of rhabdoid tumour development is time-depend-
ent in the sense that there may be a specific developmental 
time window during which the progenitor cells of rhabdoid 
tumours are vulnerable to SMARCB1 protein loss (Boyd 
et al. 2008; Biegel et al. 2014). If the cells manage to pro-
gress through this critical time period without experiencing 
complete SMARCB1 loss, then the individual harbouring 
them may not develop rhabdoid tumours despite the pres-
ence of the germline SMARCB1 mutation. This hypothesis 
is consistent with the peak incidence of rhabdoid tumours 
at 6 months of age in patients with germline SMARCB1 
mutations. Furthermore, the risk of developing a rhabdoid 
tumour decreases dramatically after 3 years of age (Eaton 
et al. 2011).
Swensen et al. (2009) investigated a four-generation 
family with members affected either by schwannomatosis 
or rhabdoid tumour (Supp. Table S5). Two schwannomas 
from different affected members of this family were biop-
sied and classified as epithelioid schwannomas. This histo-
logical subtype is very rare among schwannomas detected 
in patients with schwannomatosis (Hart et al. 2016). Fur-
thermore, both schwannomas were negative for SMARCB1 
immunostaining, indicative of a complete loss of the 
SMARCB1 protein (Swensen et al. 2009). This is in stark 
contrast to the schwannomatosis-associated tumours which 
usually exhibit mosaic SMARCB1 expression (Hulsebos 
et al. 2007; Patil et al. 2008; Smith et al. 2012c). Taken 
together, these observations suggest that schwannomas 
observed in this family (and probably also in other families 
with rhabdoid tumour and schwannomatosis) may have a 
different biology compared with classical schwannomato-
sis-associated schwannomas.
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In line with this postulate are the findings of Carter et al. 
(2012) who reported a patient with a germline SMARCB1 
frameshift mutation in exon 3 and several schwannomas 
which were classified as ‘neuroblastoma-like’ (Supp. Table 
S5). Neuroblastoma-like schwannomas are extremely 
rare; only one other case of a patient possibly affected by 
schwannomatosis and a neuroblastoma-like schwannoma 
has been reported to date (Sulhyan et al. 2015). The female 
propositus described by Carter et al. (2012) had three chil-
dren who carried the SMARCB1 mutation and two of them 
suffered from rhabdoid tumour. The propositus developed 
an epithelioid malignant peripheral nerve sheath tumour 
(MPNST) with rhabdoid features arising from a preexisting 
schwannoma. However, the malignant transformation of 
schwannomas is extremely rare and has been observed in 
only a few cases (Woodruff et al. 1994; Nayler et al. 1996; 
McMenamin and Fletcher 2001).
The above notwithstanding, malignant schwannomas 
were reported in two patients with familial schwannomato-
sis (Gonzalvo et al. 2011). However, it is unknown whether 
they carried SMARCB1 germline mutations. Furthermore, 
MPNSTs were also noted in two members of a family 
with schwannomatosis and two co-occurring SMARCB1 
alterations, a missense mutation in exon 7 (c.864C > G; 
p.Asn288Lys) and a splice-site mutation located 12-bp 
upstream of exon 9 (c.1032-12C > G) which is predicted 
to lead to the insertion of 11 bp of intronic sequence in the 
mutant transcript (Hadfield et al. 2008; Evans et al. 2012; 
Smith et al. 2012b). This insertion would be predicted to 
introduce a frameshift that would result in the introduction 
of a novel stop codon (p. Arg373fsX379*). These findings 
raised some concern about an increased MPNST risk in 
schwannomatosis patients, but neither MPNSTs nor rhab-
doid tumours were observed in a cohort of 87 patients with 
schwannomatosis, including 11 patients from seven fami-
lies (Merker et al. 2012). However, it is not known how 
many of the patients investigated by Merker et al. (2012) 
carried SMARCB1 germline mutations. Further studies 
are necessary to assess the MPNST risk for patients with 
SMARCB1 mutation-positive schwannomatosis.
A risk of malignancy may exist in those schwannoma-
tosis patients with SMARCB1 germline mutations that 
are less likely to be hypomorphic. Paganini et al. (2015a) 
reported a patient with schwannomatosis and a uterine leio-
myosarcoma. The patient had a germline SMARCB1 muta-
tion c.1118G > A involving the last nucleotide of exon 8, 
disrupting the donor splice site of intron 8. RNA analysis 
indicated that this mutation leads to the insertion of intron 
8 sequences in the transcript that would be predicted to 
result in a frameshift. The mutant RNA has been shown 
to encode a C-terminally elongated protein exhibiting a 
different amino acid sequence and a new stop codon after 
an additional 48 amino acids. LOH analysis indicated that 
the mutant SMARCB1 allele was retained in two schwan-
nomas and the leiomyosarcoma of the patient, whereas the 
wild-type allele was lost, indicative of biallelic SMARCB1 
inactivation in both types of tumour (Paganini et al. 2015a). 
Substantiating concern about an increased risk of malig-
nancy in a subset of patients with SMARCB1-positive 
schwannomatosis, Hulsebos et al. (2016) reported a type 
1 papillary renal cell carcinoma (pRCC1) in a schwanno-
matosis patient with a germline duplication of SMARCB1 
exon 7 (c.796-2246_9861 +5250dup7686) resulting in a 
premature stop codon (p.Glu330*). The chromosome 22 
carrying the mutant SMARCB1 allele was retained in the 
pRCC1 and in schwannomas from this patient, whereas the 
wild-type SMARCB1 allele and one NF2 copy were lost by 
deletion. Immunohistochemical staining revealed the com-
plete loss of SMARCB1 expression in the pRCC1 (Hulse-
bos et al. 2016) as observed in malignant rhabdoid tumours 
with biallelic SMARCB1 inactivation.
The leiomyosarcoma and the pRCC1 observed in two 
patients with SMARCB1 mutation-positive schwannomato-
sis indicate that malignancy may, indeed, occur in a subset 
of patients. However, the risk is probably dependent upon 
the SMARCB1 mutation type and may be decreased in 
patients with hypomorphic SMARCB1 mutations.
Models of tumorigenesis in SMARCB1‑associated 
schwannomatosis
The classical two-hit model of tumorigenesis (Knudson 
1971) does not seem to pertain in the tumours of patients 
with SMARCB1 germline mutations, at least in the sense 
that this model would require biallelic SMARCB1 inactiva-
tion to be sufficient for tumour initiation or growth. This 
is concluded from the observation of frequent somatic, 
tumour-specific NF2 mutations, and the loss of the second 
NF2 allele in schwannomas from patients with germline 
SMARCB1 mutations (Boyd et al. 2008; Sestini et al. 2008; 
Hadfield et al. 2008, 2010a). These findings hint at a signif-
icantly higher level of complexity than that required by the 
basic Knudson model. The loss of the second NF2 allele 
is frequently caused by the complete loss of chromosome 
22 or large portions of the long arm of chromosome 22 
(22q), including the second (wild-type) allele of SMARCB1 
(Hadfield et al. 2010a). This pattern of mutational events 
points to a 4-hit/3-step model of tumorigenesis in patients 
with SMARCB1-positive schwannomatosis (Fig. 3a): The 
first hit (and step) represents the germline SMARCB1 muta-
tion, whereas the second step involves LOH of 22q that 
removes the wild-type SMARCB1 allele and one of the two 
NF2 alleles. The third step is the somatic mutation of the 
remaining NF2 allele located on the chromosome harbour-
ing the germline SMARCB1 mutation which is retained in 
the tumour (Boyd et al. 2008; Hadfield et al. 2008; Sestini 
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et al. 2008). This 4-hit/3-step model of tumorigenesis prob-
ably also holds true for other benign tumours observed in 
patients with SMARCB1-positive schwannomatosis, since 
biallelic inactivation of SMARCB1 and NF2 has been 
observed in a meningioma and leiomyoma of patients with 
germline SMARCB1 mutations (van den Munckhof et al. 
2012; Hulsebos et al. 2014b).
LOH of 22q in tumours from patients with germline 
SMARCB1 mutations does not seem to be mediated by 
mitotic recombination, a mechanism frequently causing 
LOH of other tumour suppressor genes (Makishima and 
Maciejewski 2011; Garcia-Linares et al. 2011; Stewart 
et al. 2012). In eight tumours from patients with germline 
SMARCB1 mutations, LOH of 22q was found to be caused 
exclusively by whole chromosome loss or large deletions 
within 22q, but not by mitotic recombination (Hadfield 
et al. 2010a). Copy-number neutral LOH of the NF2 locus 
indicative of mitotic recombination was also not observed 
in 17 schwannomas from patients with germline SMARCB1 
mutations analysed by Piotrowski et al. (2014). By contrast, 
mitotic recombination accounts for 19% of the LOH events 
in NF2-associated schwannomas (14 of 72 schwannomas 
analysed) and 23% (5/22) of schwannomas from schwan-
nomatosis patients without germline SMARCB1 muta-
tions (Hadfield et al. 2010a). The observation that LOH in 
schwannomas of patients with SMARCB1 germline muta-
tions is not mediated by mitotic recombination supports the 
4-hit/3-step model of tumorigenesis from the standpoint of 
maximum parsimony (Fig. 3a). Although mitotic recombi-
nation would lead to biallelic inactivation of SMARCB1 by 
reduplication of the mutant SMARCB1 allele, the wild-type 
NF2 allele would be preserved. Two additional independ-
ent mutational events would then be required to inactivate 
both NF2 alleles. Hence, mitotic recombination would make 
four steps of mutation necessary to inactivate both alleles 
of SMARCB1 and NF2 instead of three as suggested by the 
model of tumorigenesis for SMARCB1-positive schwanno-
matosis depicted in Fig. 3a.
Although the 4-hit/3-step model accounts for the major-
ity of the tumours in the cases of SMARCB1 mutation-
positive schwannomatosis, biallelic inactivation of the NF2 
gene is not observed in all schwannomas (Boyd et al. 2008; 
Hadfield et al. 2008, 2010a; Sestini et al. 2008; Hulse-
bos et al. 2007, 2016). It is estimated that at least 19% of 
schwannomas of patients with germline SMARCB1 muta-
tions exhibit only mono-allelic NF2 inactivation (Supp. 
Table S6) (Boyd et al. 2008; Hadfield et al. 2008, 2010a; 
Sestini et al. 2008). In this subgroup of tumours, the inacti-
vation of only one NF2 allele may be sufficient to promote 
the proliferation of the cells with biallelic SMARCB1 inac-
tivation. Since the LOH events in SMARCB1 mutation-pos-
itive schwannoma usually include large parts of 22q (Had-
field et al. 2010a), other tumour suppressor genes located 
on 22q will also be haploinsufficient and this may contrib-
ute to schwannoma growth. One of these suspected tumour 
suppressor genes is likely to be LZTR1.
Fig. 3  Models of tumorigenesis 
in schwannomatosis. a Four-
hit/3-step model in patients 
with an heterozygous germline 
SMARCB1 mutation (first hit 
and step). The second step 
includes loss of heterozygosity 
(LOH) of 22q which removes 
the wild-type SMARCB1 allele 
and one of the two NF2 alleles. 
The third step is the somatic 
mutation of the other NF2 allele 
located on the chromosome har-
bouring the germline SMARCB1 
mutation. b Four-hit/3-step 
model of tumorigenesis in 
patients with an heterozygous 
germline LZTR1 mutation (first 
hit and step). c Five-hit/3-step 
model of tumorigenesis in 
schwannomatosis. The LOH 
event which removes one wild-
type LZTR1 allele and one copy 
of NF2 automatically leads 
to the loss of one SMARCB1 
allele, which represents the fifth 
mutational hit
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Germline mutations in LZTR1
Germline SMARCB1 mutations account for 48% of famil-
ial and 9.8% of sporadic schwannomatosis cases (Supp. 
Table S2) indicative of probable locus heterogeneity and 
the existence of additional schwannomatosis predisposi-
tion genes. Piotrowski et al. (2014) analysed 3.72 Mb of 
highly conserved DNA sequence within different regions 
of 22q, including parts of the previously defined linkage 
interval postulated to harbour schwannomatosis predispo-
sition genes (MacCollin et al. 2003) and the region of the 
CABIN1 gene which has been suggested to be important 
in schwannomatosis (Buckley et al. 2005). The 3.72 Mb of 
highly conserved sequence were analysed by targeted next-
generation sequencing which indicated germline muta-
tions within in the LZTR1 (leucine zipper-like transcrip-
tional regulator 1) gene in patients with schwannomatosis 
but lacking SMARCB1 mutations (Piotrowski et al. 2014). 
LZTR1 is located 2.8 Mb centromeric to SMARCB1 and 
8.7 Mb centromeric to NF2 (Fig. 2), and is included in the 
1.5–3-Mb region which is deleted in individuals with the 
DiGeorge syndrome. The protein encoded by LZTR1 con-
tains Kelch- and BTB/POZ-domains and localizes to the 
Golgi complex (Nacak et al. 2006). It has also been shown 
to be an adaptor of the cullin 3-containing E3 ubiquitin 
ligase complex (Frattini et al. 2013). Somatic mutations in 
LZTR1 occur in 22% of glioblastomas (Frattini et al. 2013) 
and in several other cancers according to the Catalogue of 
Somatic Mutations in Cancer (COSMIC) database (Forbes 
et al. 2008). The biallelic inactivation of LZTR1 in glioblas-
tomas, and the observation that LZTR1 inactivation drives 
self-renewal and growth of glioma spheres, are indicative 
of LZTR1 acting as a classic tumour suppressor gene (Frat-
tini et al. 2013).
Piotrowski et al. (2014) identified LZTR1 germline 
mutations in 16 of 20 unrelated schwannomatosis patients 
(80%). Among these, 20 patients were 6 familial schwan-
nomatosis cases and LZTR1 mutations were found in all 
of them. Eleven of the twenty patients analysed were con-
firmed sporadic cases and eight of these (73%) had LZTR1 
mutations (Piotrowski et al. 2014). Such a high rate of 
LZTR1 mutation in SMARCB1 mutation-negative schwan-
nomatosis patients was not, however, observed in subse-
quent studies (Hutter et al. 2014; Paganini et al. 2015b; 
Smith et al. 2015). In these latter studies, only 22–30% of 
sporadic cases and 38% of familial cases exhibited LZTR1 
mutations (Supp. Table S7). This difference in the propor-
tion of LZTR1 mutation-positive schwannomatosis cases 
detected may be due to the adoption of different selection 
criteria for the patients being analysed. Piotrowski et al. 
(2014) exclusively studied patients with a molecularly con-
firmed diagnosis of schwannomatosis. This implies that 
two different somatic NF2 mutations were identified in two 
tumours of a given patient as well as the loss of chromo-
some 22q encompassing the wild-type NF2 allele. By con-
trast, the studies with lower LZTR1 mutation detection rates 
mostly focussed upon patients diagnosed with schwanno-
matosis on the basis of clinical criteria according to Plotkin 
et al. (2013) and who were negative for SMARCB1 muta-
tions. Consequently, the studies reporting lower LZTR1 
mutation detection rates included a more heterogeneous 
group of patients whose schwannomas may not have been 
characterized by biallelic NF2 inactivation. Neverthe-
less, these studies serve to confirm that LZTR1 is a major 
schwannomatosis predisposition gene.
Schwannomatosis-associated LZTR1 mutations were 
found in nearly all exons; thus, no positional preference 
of mutations was observed (Hutter et al. 2014; Piotrowski 
et al. 2014; Paganini et al. 2015a; Smith et al. 2015). In 
contrast to this situation, SMARCB1 mutations causing 
schwannomatosis are predominantly located at the 5′ or 
3′ end of the gene (Smith et al. 2014). Of the 59 LZTR1 
mutations identified to date, at least 28 (47%) were protein-
truncating, whilst all of the 23 missense mutations were 
predicted to be deleterious (Supp. Table S8). These findings 
suggest that the majority of schwannomatosis-associated 
LZTR1 mutations are not hypomorphic. Somatic loss of 
the wild-type LZTR1 allele is predicted to lead to biallelic 
loss of LZTR1 in tumours of germline mutation carriers. 
However, the type of the LZTR1 mutation would appear to 
influence LZTR1 protein expression in tumours. Schwan-
nomas from patients with nonsense or frameshift LZTR1 
mutations do not exhibit LZTR1 protein immunostaining, 
whereas patients carrying splicing or missense variants 
showed reduced immunostaining (Paganini et al. 2015b). 
By contrast, schwannomas from LZTR1-unrelated schwan-
nomatosis patients, as well as patients with NF2, showed 
diffuse but positive LZTR1 immunostaining. Whether this 
variability has any effect on schwannoma growth or loca-
tion is unclear but clearly warrants further investigation.
LZTR1 mutations in unaffected carriers
Ten unrelated and clinically unaffected LZTR1 mutation 
carriers have been identified who had relatives harbouring 
the same mutation and were affected by schwannomatosis 
(Supp. Table S8). Eight of these ten apparently nonpene-
trant LZTR1 mutations were protein-truncating and highly 
likely to be deleterious. Even though not all clinically unaf-
fected LZTR1 mutation carriers have been investigated by 
MRI [precluding the unambiguous exclusion of the occur-
rence of minor lesions, such as intrafascicular microle-
sions described by Farschtschi et al. (2016)], many of these 
individuals are of advanced age and some clinical symp-
toms should already have become apparent. The reason 
for the incomplete penetrance of these LZTR1 mutations is 
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currently unclear, but it may be that somatic mosaicism for 
the LZTR1 mutations accounts for the absence of clinical 
symptoms in the unaffected mutation carriers who passed 
on the mutations to the affected family members. Although 
the respective LZTR1 mutations were detected in high pro-
portions of peripheral blood cells of the unaffected family 
members, this should not be held to imply that numerous 
Schwann cell progenitor cells also harbour the mutation. 
We postulate that the LZTR1 mutations in the unaffected 
probands are of post-zygotic origin and are present in a 
minority of Schwann cell precursors. The haematopoietic 
progenitor cells carrying the LZTR1 mutation may pos-
sess a selective growth advantage, giving rise to a high 
proportion of mutation-positive blood cells. This situation 
would be reminiscent of patients with neurofibromatosis 
type 1 (NF1) and somatic mosaicism for a large deletion 
in the NF1 gene region spanning 1.2 Mb. The patients have 
a high proportion of blood cells carrying the NF1 dele-
tion (>90%); a much lower proportion of cells with the 
NF1 deletion has, however, been detected in the fibroblasts 
and urine of these patients (Kehrer-Sawatzki and Cooper, 
2008; Roehl et al. 2012). Somatic mosaicism due to a post-
zygotic mutation and selective growth advantage of LZTR1 
haploinsufficient blood cells may, therefore, be responsible 
for the apparently incomplete penetrance of some LZTR1 
mutations. However, it is possible that the LZTR1 mutation 
in the unaffected family members is, indeed, constitutional 
and that the lack of clinical symptoms manifested by these 
LZTR1 mutation carriers may be caused by as yet unidenti-
fied modifying genes.
LZTR1 germline mutations and associated tumour 
spectrum
So far, patients with schwannomatosis and LZTR1 germline 
mutations have not been reported to exhibit meningiomas, 
in contrast to patients with SMARCB1 germline mutations 
(Hutter et al. 2014; Piotrowski et al. 2015; Paganini et al. 
2015b; Smith et al. 2015, 2016). These findings suggest 
that LZTR1 mutations do not predispose to meningiomas. 
However, unilateral vestibular schwannomas can occur in 
patients with LZTR1 mutation-positive schwannomato-
sis. Recently, Smith et al. (2016) demonstrated that 5 of 
70 patients (7%) presenting with a unilateral vestibular 
schwannoma and at least two nonintradermal, nonvestibu-
lar schwannomas have germline LZTR1 mutations; hence, 
these individuals have schwannomatosis rather than NF2 
even, although they would fulfil current diagnostic crite-
ria for NF2. These findings further evidence the overlap 
between schwannomatosis and NF2.
In contrast to LZTR1-associated schwannomatosis, 
SMARCB1 mutations are probably less likely to predispose 
to unilateral vestibular schwannomas. So far, only one 
solitary case of a unilateral vestibular schwannoma in a 
putative SMARCB1-associated schwannomatosis family 
has been reported (Wu et al. 2015). However, this report 
remains inconclusive, since, although the SMARCB1 muta-
tion was identified in a schwannoma of family member 
with a unilateral schwannoma, this mutation was not con-
firmed to be present in the germline of this patient or in any 
other affected family member. Further studies are, there-
fore, needed to investigate a possible association between 
unilateral vestibular schwannomas and germline SMARCB1 
mutations.
Segmental schwannomatosis
In approximately one-third of schwannomatosis patients, 
tumours are anatomically restricted to a single limb or a 
few adjacent spinal segments, thereby manifesting what 
appears to be a segmental form of the disease (MacCol-
lin et al. 2005; Merker et al. 2012). Two patients have 
been identified with clinically symptomatic schwanno-
mas restricted to one limb, suggestive of somatic mosai-
cism; however, germline LZTR1 mutations were identified 
in these patients (Farschtschi et al. 2016). Furthermore, 
microstructural magnetic resonance neurography indicated 
the presence of small peripheral nerve lesions (‘microle-
sions’) in clinically unaffected limbs of these two patients. 
Three additional patients were included in this study and 
these individuals also exhibited symptomatic schwannomas 
that were restricted to one limb and fascicular microlesions 
along the nerves of other extremities. Germline mutations 
in LZTR1, SMARCB1, and NF2 were not observed in these 
patients. However, the analysis of a schwannoma from 
each of these patients indicated a somatic NF2 gene muta-
tion which is not unusual, since somatic NF2 mutations 
are frequently observed in schwannomas. The occurrence 
of asymptomatic peripheral nerve microlesions in multiple 
body parts in these five patients with segmental occurrence 
of clinically symptomatic schwannomas suggests that the 
disease manifestation is more widespread and not sim-
ply restricted to a single body segment (Farschtschi et al. 
2016).
Models of tumorigenesis 
in LZTR1 mutation‑positive schwannomatosis
In most schwannomas from patients harbouring LZTR1 
germline mutations, the chromosome 22 is retained that 
harbours the germline LZTR1 mutation and an NF2 allele 
with a somatically acquired tumour-specific mutation. 
The other copy of chromosome 22 is lost or partially 
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deleted, including the wild-type alleles of LZTR1 and NF2 
(Piotrowski et al. 2014; Paganini et al. 2015b; Smith et al. 
2015) (Fig. 3b). Consequently, the mutational mechanism 
would appear to be similar to the 4-hit/3-step model of 
tumorigenesis observed in schwannomas of patients with 
germline SMARCB1 mutations (Fig. 3a). However, since 
SMARCB1 is located between LZTR1 and NF2, both of 
which are lost by deletion or monosomy 22q, it is inevitable 
that one of the two SMARCB1 alleles is also lost. Hence, 
in practice, tumorigenesis in LZTR1-associated schwan-
nomatosis should follow a 5-hit/3-step model (Fig. 3c). 
Moreover, schwannomas of patients with germline 
SMARCB1 mutations may follow the 5-hit/3-step model 
if the chromosomal region on chromosome 22 exhibiting 
LOH also includes LZTR1. Since LZTR1 is located proxi-
mal to SMARCB1 and NF2, the loss of one LZTR1 allele is 
dependent upon the extent of the region showing LOH. It 
is, however, unknown if the loss of one LZTR1 allele con-
tributes to tumour growth. A mutation of the second LZTR1 
allele would be necessary for the biallelic inactivation of 
this tumour suppressor gene. It remains to be investigated if 
schwannomas following either the 4-hit or the 5-hit model 
of tumorigenesis would exhibit differences in growth rate, 
proliferation index, or location.
The 3-step model of tumorigenesis appears to apply to 
the majority of LZTR1 mutation-positive schwannomas. 
However, not all schwannomas from patients with LZTR1 
germline mutations exhibit this pattern of mutational events 
similar to that observed in some schwannomas of patients 
with germline SMARCB1 mutations. Instead of the biallelic 
NF2 inactivation implied by this model, mono-allelic NF2 
inactivation was observed in 10 of the 28 (37%) schwan-
nomas from patients with germline LZTR1 mutations 
analysed by Paganini et al. (2015b). In eight of these ten 
schwannomas, 22q LOH was detected, but an intragenic 
NF2 gene mutation could not be found, whereas two of ten 
schwannomas harboured an intragenic NF2 mutation, while 
heterozygosity of 22q markers was retained (Paganini et al. 
2015b). Mono-allelic NF2 inactivation was detected in 3 
of 11 (27%) schwannomas from LZTR1 mutation-positive 
patients studied by Smith et al. (2015). However, it cannot 
be excluded that biallelic NF2 inactivation was not detected 
in these studies owing to the limited resolution of the meth-
odology employed. Further analysis would be necessary to 
establish whether alternative mechanisms, such as epige-
netic silencing of NF2 gene expression, could be involved 
in the biallelic NF2 inactivation in these tumours. Indeed, 
hypermethylation of the NF2 promoter region has been 
shown to be frequent in schwannomas and could, therefore, 
represent an alternative mechanism of NF2 inactivation 
(Kino et al. 2001; Gonzalez-Gomez et al. 2003).
Predisposition to bilateral vestibular 
schwannomas in patients with NF2 but not 
schwannomatosis
NF2 mutations are detected in schwannomas irrespective 
of whether they occur sporadically or in the context of 
schwannomatosis or NF2 (Jacoby et al. 1996; Mohyud-
din et al. 2002; Hadfield et al. 2010a). However, the tim-
ing of origin of the underlying mutations is different which 
may well impact upon the spectrum of tumours observed, 
in particular bilateral vestibular schwannomas (BVS). 
In patients with NF2, the germline NF2 gene mutation 
is clearly going to be present during the early embryonic 
development and subsets of Schwann cell precursors may 
be especially vulnerable to NF2 haploinsufficiency during 
a specific developmental time period. This could account 
for the high frequency (>90%) of BVS in patients with ger-
mline NF2 mutations. By contrast, in patients with sporadi-
cally occurring schwannomas and in patients with schwan-
nomatosis, the somatic NF2 mutations occur rather later 
during development and neither group of patients exhibits 
BVS. Furthermore, the histology and growth pattern of ves-
tibular schwannomas (VS) in NF2 are different from that 
of sporadic VS. VS in NF2 are multifocal, appearing “like 
a bunch of grapes” around the vestibular nerve (Stivaros 
et al. 2015). Remarkably, these multifocal tumours exhibit 
the same first-hit NF2 mutation but different, foci-specific 
second-hit NF2 mutations, indicative of the polyclonal-
ity of these tumours (Mohyuddin et al. 2002; Dewan et al. 
2015). NF2-associated VS grow at multiple sites along the 
eighth cranial nerve and these tumour foci later merge into 
one tumour mass with a multi-lobulated histological pattern 
(Stivaros et al. 2015). By contrast, sporadic VS are usu-
ally single tumours arising from the vestibular nerve at the 
porus acusticus. NF2-associated VS are often more aggres-
sive and difficult to treat than sporadic VS because of their 
growth pattern and the involvement of nerves. To date, 
seven cases of unilateral VS have been reported in patients 
with schwannomatosis (Smith et al. 2012a, 2015, 2016; Wu 
et al. 2015; Mehta et al. 2016), but neither their histology 
nor their growth pattern has been described.
Involvement of SMARCB1 in NF2‑associated 
schwannomas
The main focus of this review is schwannomatosis, but the 
considerable clinical overlap between NF2 and schwanno-
matosis, as well as the shared mutational mechanisms (such 
as LOH of 22q), render it likely that a similar set of genes 
is involved in both conditions.
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NF2-associated and sporadically occurring schwanno-
mas are known to be caused by biallelic inactivation of the 
NF2 gene (Stemmer-Rachamimov et al. 1997; reviewed 
by Evans 2009). LOH of large parts of 22q is observed in 
67% of NF2-associated and 56% of sporadic schwanno-
mas (Hadfield et al. 2010a). However, copy-number neutral 
LOH mediated by mitotic recombination is relatively fre-
quent, observed in 19% of NF2-associated schwannomas 
and in 6% of sporadic schwannomas. Nevertheless, LOH 
causing copy-number loss in 22q represents the most fre-
quent second-hit mutation observed in ~50% of all NF2-
associated schwannomas (Hadfield et al. 2010a) and 69% 
of sporadic schwannomas (Agnihotri et al. 2016). Since 
the LOH frequently involves large portions of chromo-
some 22q (Mantripragada et al. 2003; Warren et al. 2003), 
it is likely to be associated with the concomitant loss of 
several tumour suppressor genes. It has been suggested 
that more than two mutations are necessary for vestibular 
schwannoma development in NF2 patients (Woods et al. 
2003). Indeed, LOH involving large parts of 22q is a key 
mutational step to mediate the concurrent loss of NF2, 
SMARCB1 and eventually also LZTR1. It should be noted 
that 83% of all NF2-associated schwannomas exhibit a 
mosaic SMARCB1 protein expression pattern resulting 
from intermixed tumour cells with and without SMARCB1 
expression (Patil et al. 2008). This mosaic pattern has also 
been observed in 93% of schwannomas from patients with 
familial schwannomatosis and 55% of schwannomas from 
patients with sporadic schwannomatosis (Patil et al. 2008). 
However, only 5% of sporadically occurring schwanno-
mas in patients without NF2 or schwannomatosis exhibit 
mosaic SMARCB1 expression. These findings suggest the 
frequent involvement of SMARCB1 in the pathogenesis of 
NF2 and schwannomatosis-associated tumours but not in 
sporadic schwannomas. Remarkably, the loss of LZTR1 
immunostaining was not observed in seven vestibular 
schwannomas from seven unrelated NF2 patients (Paganini 
et al. 2015b).
Somatic mosaicism in schwannomatosis 
and unknown schwannomatosis predisposition 
genes
Mutation screening performed with blood-derived DNA 
from patients with schwannomatosis suggests that 38% of 
familial cases are caused by LZTR1 mutations and 48% by 
mutations in SMARCB1. Thus, in 14% of familial schwan-
nomatosis cases, predisposing germline mutations have 
not been identified as yet. In sporadic schwannomatosis, 
30% of the cases are caused by germline LZTR1 mutations 
and 10% by germline SMARCB1 mutations (Supp. Tables 
S2 and S7) (Boyd et al. 2008; Hadfield et al. 2008; Sestini 
et al. 2008; Rousseau et al. 2011; Smith et al. 2012b, 2014, 
2015; Hutter et al. 2014; Paganini et al. 2015b). Accord-
ing to these assessments, the causative mutational events 
remain unknown in 60% of all sporadic schwannomatosis 
patients (Fig. 4). It is possible that a proportion of patients 
without intragenic germline SMARCB1 or LZTR1 muta-
tions may harbour mutations in remote-acting regulatory 
regions or possess epimutations that would silence these 
genes, but this has not so far been investigated. Alterna-
tively, somatic mosaicism for SMARCB1 or LZTR1 muta-
tions could be responsible for the relatively high proportion 
of sporadic schwannomatosis patients without detectable 
germline SMARCB1 and LZTR1 mutations. However, no 
detectable mosaicism was found in six patients without 
SMARCB1 and LZTR1 mutations in their blood, as deter-
mined by analysing multiple schwannomas from these 
patients. In these tumours, neither SMARCB1 nor LZTR1 
mutations were detected. Instead, tumour-specific somatic 
NF2 mutations were identified which are known to be 
Fig. 4  Estimation of the relative proportions of familial and sporadic 
patients with germline mutations in LZTR1 or SMARCB1 among 
patients who fulfil the clinical diagnostic criteria for schwannoma-
tosis. These estimates are derived from studies of individuals diag-
nosed with schwannomatosis according to clinical diagnostic criteria 
without preselection for those patients who have been shown to har-
bour different somatic NF2 gene mutations in at least two different 
schwannomas (Boyd et al. 2008; Hadfield et al. 2008; Sestini et al. 
2008; Rousseau et al. 2011; Hutter et al. 2014; Smith et al. 2012b, 
2014, 2015)
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frequent in schwannomatosis (Paganini et al. 2015b; Smith 
et al. 2015). Mosaicism for somatic LZTR1 or SMARCB1 
mutations in patients with schwannomatosis has not so 
far been reported and only one case of germline (gonadal) 
mosaicism for a SMARCB1 mutation has been identi-
fied (Hulsebos et al. 2010). Taken together, we surmise 
that it is unlikely that unidentified somatic mosaicism for 
SMARCB1 or LZTR1 mutations would account for the high 
number of sporadic schwannomatosis cases without identi-
fied mutations.
On the other hand, somatic mosaicism for an NF2 gene 
mutation may be much more frequent in patients consid-
ered to have schwannomatosis, but who do not carry ger-
mline SMARCB1 or LZTR1 mutations as suggested by 
Widemann et al. (2014). Indeed, some NF2 patients with 
somatic mosaicism for an NF2 gene mutation fulfil the 
diagnostic criteria for schwannomatosis (Plotkin et al. 
2013). Further, somatic mosaicism in NF2 is not rare, since 
it is detected in 33% of sporadic NF2 cases with bilateral 
vestibular schwannomas and in up to 60% of patients with 
unilateral vestibular schwannoma (Moyhuddin et al. 2003; 
Evans et al. 2007). In patients with mosaic NF2, the ‘first-
hit’ NF2 gene mutation is often present at a low level in 
blood cells and is sometimes only detectable in tumour tis-
sue but not in blood cells (Evans et al. 1998, 2007; Kluwe 
and Mautner 1998; Kluwe et al. 2003; Paganini et al. 
2014; Spyra et al. 2015; Smith et al. 2016). To distinguish 
between mosaic NF2 and schwannomatosis, it is necessary 
to perform NF2 mutation testing in more than one tumour 
from a given patient who does not carry a germline muta-
tion in SMARCB1 or LZTR1 as determined by blood cell 
analysis. Mosaic NF2 would be confirmed if the same NF2 
mutation (first-hit) is observed in two independent tumours 
from a given patient in addition to different tumour-specific 
(second-hit) mutations of the other NF2 allele. This strat-
egy has been successfully pursued by Castellanos et al. 
(2015) who investigated a female patient with several pain-
ful schwannomas confined to one limb. In the schwan-
nomas, but not the blood cells of this patient, Castellanos 
et al. detected a large deletion encompassing not only the 
NF2 gene but also large parts of chromosome 22 telomeric 
to NF2. Neither SMARCB1 nor LZTR1 was included within 
the bounds of this deletion, since these genes are located 
centromeric to NF2. Importantly, the deletion exhibited the 
same breakpoint in both schwannomas from this patient, 
indicating that the deletion represented the first-hit muta-
tion. By contrast, two different intragenic NF2 gene muta-
tions were identified which were specific to each tumour 
and hence represented the second-hit mutations. Conse-
quently, the genetic diagnosis of this patient was mosaic 
NF2 rather than schwannomatosis. The study of Castella-
nos et al. (2015) demonstrates how important it is to dis-
tinguish between first-hit and second-hit mutations by the 
meticulous analysis of deletion breakpoints and extent of 
LOH to arrive at a precise diagnosis by means of molecular 
genetic testing.
Even if it is assumed that a certain proportion of unex-
plained schwannomatosis cases are caused by somatic 
mosaicism for an NF2 gene mutation, a subset of these 
unexplained cases may well be caused by mutations in a 
gene or genes that still remain to be identified. This subset 
should comprise at least 27% of all unexplained sporadic 
schwannomatosis cases, as concluded from the analysis 
of Piotrowski et al. (2014). To minimize the confound-
ing influence of patients with somatic mosaicism for NF2 
gene mutations among patients with suspected schwanno-
matosis, Piotrowski et al. (2014) included in their analysis 
of SMARCB1 mutation-negative patients only those indi-
viduals who exhibited different somatic NF2 gene muta-
tions and LOH of chromosome 22q in at least two different 
tumours analysed. They were able to detect LZTR1 muta-
tions in all six familial schwannomatosis cases analysed and 
in 73% of sporadic cases who were SMARCB1 mutation-
negative. Consequently, 27% of sporadic schwannomato-
sis patients who do not exhibit germline NF2, SMARCB1, 
and LZTR1 mutations, but who do display tumour-specific 
biallelic NF2 inactivation, could, in principle, be caused by 
mutations in hitherto unidentified gene(s). Since Piotrowski 
et al. (2014) analysed a preselected group of patients and 
did not include those patients who, although fulfilling 
the diagnostic criteria for schwannomatosis, lacked bial-
lelic NF2 inactivation in their tumours, the proportion of 
unexplained sporadic schwannomatosis cases caused by 
mutations in other as yet unidentified genes could be even 
higher. Mutations in these hitherto unidentified genes may 
also account for familial cases, since Paganini et al. (2015b) 
investigated six cases with familial schwannomatosis, who 
were negative for both SMARCB1 and LZTR1 mutations. It 
is possible that some of the unexplained cases are caused 
by gross rearrangements, multi-exon deletions, or duplica-
tions of SMARCB1 or LZTR1, but these lesions are usually 
much rarer than intragenic mutations and they have not 
been detected by any of the MLPA or SNP array analyses 
so far performed (Hadfield et al. 2010a; Smith et al. 2015). 
Taken together, we conclude that there may well be further 
schwannomatosis predisposition genes that still remain to 
be identified.
One possible candidate has been put forward by Zhang 
et al. (2014) who identified a heterozygous missense muta-
tion, c.622G > C, p.Asp208His, in the COQ6 gene on 
chromosome 14q24.3 segregating with the disease in a 
family with schwannomatosis. The affected family mem-
bers did not appear to harbour germline mutations in 
SMARCB1, LZTR1, or NF2; nor were somatic mutations of 
these genes detected in two schwannomas from two fam-
ily members. Furthermore, immunohistochemical staining 
142 Hum Genet (2017) 136:129–148
1 3
indicated normal protein expression levels of SMARCB1, 
LZTR1, and NF2 in both schwannomas. The latter finding 
is unusual, since mosaic SMARCB1 expression has been 
observed in 93% of schwannomas derived from patients 
with familial schwannomatosis (Patil et al. 2008). However, 
Zhang et al. (2014) did not identify biallelic inactivation 
of COQ6 gene in schwannomas of this family. Although 
the deleterious effects of the COQ6 missense mutation 
were validated by its lack of complementation in a coq6-
deficient yeast mutant, there was no evidence for either a 
dominant-negative effect or a toxic gain of function of the 
missense COQ6 variant detected; hence, the mechanism 
of tumorigenesis in this schwannomatosis family remains 
unexplained. As opined by Trevisson et al. (2015), further 
studies are necessary to ascertain whether COQ6 might 
play a role in the etiology of schwannomatosis.
SMARCB1, LZTR1, and NF2 clearly function as clas-
sical tumour suppressor genes, and hence, it is not unrea-
sonable to suppose that other schwannomatosis predisposi-
tion genes might also act in an onco-suppressive manner. 
Although it cannot be excluded that another schwanno-
matosis predisposition gene is located elsewhere in the 
genome, it is tempting to speculate that it would be located 
on chromosome 22, because in schwannomas, this chro-
mosome is frequently affected by LOH. Consequently, the 
underlying model of tumorigenesis in these unexplained 
cases could also include three mutational steps similar to 
the above-mentioned model that accounts for SMARCB1 
and LZTR1 mutation-positive tumours. Pinto et al. (2014) 
performed a detailed annotation of the chromosome 
22-encoded proteome and identified protein products 
encoded by 367 genes. Among them were proteins encoded 
by 22 cancer-associated genes—these may represent good 
candidates for further schwannomatosis predisposition 
genes. Finally, a number of other candidate genes may be 
found among the genes shown by Agnihotri et al. (2016) 
to be somatically mutated in sporadic schwannomas (see 
below).
The comprehensive genome-wide analysis of the muta-
tional landscape of somatic mutations in schwannomas of 
patients with schwannomatosis has not so far been per-
formed but would improve our understanding of the tumor-
igenic process in schwannomatosis. Such an analysis could 
also help to identify altered cellular pathways that would 
reveal the involvement of yet unidentified schwannomato-
sis predisposition genes. In a recent study, Agnihotri et al. 
(2016) performed whole-exome sequencing of 13 cranial 
and 13 spinal schwannomas occurring as sporadic tumours 
in patients without NF2 or schwannomatosis. No germline 
mutations or deletions were detected for NF2, LZTR1, 
SMARCB1, or SMARCE1. However, these authors identi-
fied 441 somatic single-nucleotide variants located in the 
exomes of these 26 schwannoma samples, corresponding to 
0.16 mutations per coding megabase. This number of muta-
tions is quite low, and comparable to other low-mutation-
rate tumours, such as Ewing and rhabdoid sarcomas (Law-
rence et al. 2013). Agnihotri et al. (2016) observed somatic 
NF2 mutations and/or 22q loss in 96/125 samples (77%). 
Somatic LZTR1 mutations were identified in 2/26 schwan-
nomas (8%), but somatic SMARCB1 mutations were not 
observed. Recurrent but low-frequency mutations were 
identified in eight different genes, and Agnihotri et al. vali-
dated their findings by targeted sequencing of these genes 
in an additional 99 sporadic schwannomas. They detected 
mutations in DDR1, encoding a receptor tyrosine kinase 
activated in lung cancer and other tumour types (Ambro-
gio et al. 2016), in 14/125 (11%) of the schwannomas. 
Other recurrently mutated genes were TSC1 (mutated in 
9% of tumours), CAST (8%), ALPK2 (8%), TSC2 (7%), 
and TAB 3 (3%). Furthermore, 29% (37/125) of all schwan-
nomas harboured inactivating mutations in either ARID1A 
or ARID1B, which along with SMARCB1, encode proteins 
of the SWI/SNF chromatin-remodeling complex (Nie et al. 
2000). Agnihotri et al. (2016) also discovered a somatic 
recurrent in-frame fusion involving SH3PXD2A and 
HTRA1, arising through a balanced translocation on chro-
mosome 10q in 12/25 (10%) of schwannomas analysed by 
RNA-sequencing. Expression of the SH3PXD2A-HTRA1 
fusion in Schwann cells and a schwannoma cell line 
resulted in increased cell proliferation, invasive growth, 
and in vivo tumorigenesis. Whether this somatic fusion also 
contributes to tumorigenesis in the context of schwannoma-
tosis remains to be investigated.
Conclusion and perspective
Germline mutations in either SMARCB1 or LZTR1 pre-
dispose to the development of multiple schwannomas in 
patients with schwannomatosis. In addition, the NF2 gene 
is involved in schwannomatosis-associated tumorigenesis, 
since it is frequently inactivated in schwannomas.
However, determining the complete mutational spectrum 
of all three genes, LZTR1, SMARCB1, and NF2, by com-
prehensive mutation testing as suggested in Fig. 5, has not 
so far been attempted. Such comprehensive testing would 
help to classify schwannomas in terms of the number of 
mutational hits and the biallelic or mono-allelic inactiva-
tion of these tumour suppressor genes (TSGs). A genetic 
classification of schwannomas might correlate with tumour 
growth patterns, physical location, and response to therapy.
From the data so far available, it is already clear that 
at least two and sometimes three TSGs are inactivated in 
schwannomas from patients with schwannomatosis, an 
event which is frequently mediated by LOH, including 
large portions of 22q. The possible involvement of further 
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TSGs in predisposition to schwannomatosis would serve to 
render the mutational model even more complex.
Recurrent cancer-associated deletions involving several 
linked TSGs have also been observed on chromosomes 7q, 
8p, and 9p in different types of tumour (Krimpenfort et al. 
2007; Asou et al. 2009; Solimini et al. 2012; Xue et al. 
2012; Kotini et al. 2015). The concomitant loss of several 
TSGs as a consequence of a single mutational event, such 
as a gross chromosomal deletion, may disclose an interac-
tive or cooperative effect in the sense that the biallelic inac-
tivation and haploinsufficiency of several TSGs collectively 
promote tumorigenesis of the affected cells, since several 
signalling pathways and other cellular processes are con-
currently disturbed. Schwannomatosis serves as a paradigm 
for such cooperative tumorigenic effects mediated by the 
concomitant loss of several linked TSGs.
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